Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
948
Views
0
CrossRef citations to date
0
Altmetric
Research Article

MiR-181a-2-3p as a potential diagnostic and prognostic marker for myelodysplastic syndrome

Xiaolin Lianga Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China;b Key Laboratory of Hematology, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Zeyan Shia Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China;b Key Laboratory of Hematology, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Xiaoke Huanga Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Chengyao Wana Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Shanhu Zhua Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Meiqing Wua Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Zhongqing Lia Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Zhongyuan Tanga Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Jing Lia Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China;b Key Laboratory of Hematology, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Weihua Zhaoa Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China;b Key Laboratory of Hematology, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Jun Luoa Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China;b Key Laboratory of Hematology, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
&
Zhenfang Liua Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China;b Key Laboratory of Hematology, Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1246-1252 | Received 05 Jul 2022, Accepted 15 Nov 2022, Published online: 29 Nov 2022

Figures & data

Table 1. Clinical features of MDS patients.

Figure 1. Expression of miR-181a-2-3p in each group. (A) Relative expression of miR-181a-2-3p in MDS patients (n = 70) and normal controls (n = 32). (B) Relative expression of miR-181a-2-3p in the newly diagnosed MDS group (n = 54), sAML group (n = 16), and normal controls group (n = 32). (C) Relative expression of miR-181a-2-3p in the relatively low risk group (n = 16), the relatively high risk group (n = 38), sAML group (n = 16), and normal controls group (n = 32). (D) Relative expression of miR-181a-2-3p in each WHO subtype of MDS patients.

Figure 1. Expression of miR-181a-2-3p in each group. (A) Relative expression of miR-181a-2-3p in MDS patients (n = 70) and normal controls (n = 32). (B) Relative expression of miR-181a-2-3p in the newly diagnosed MDS group (n = 54), sAML group (n = 16), and normal controls group (n = 32). (C) Relative expression of miR-181a-2-3p in the relatively low risk group (n = 16), the relatively high risk group (n = 38), sAML group (n = 16), and normal controls group (n = 32). (D) Relative expression of miR-181a-2-3p in each WHO subtype of MDS patients.

Table 2. Comparison of clinical and molecular characteristics with miR-181-2-3p expression in MDS patients.

Figure 2. Areas under the curve (AUC) of receiver operating characteristic (ROC) curves using miR-181a-2-3p for (A) differentiating patients with MDS from normal controls, and (B) distinguishing sAML from newly diagnosed MDS patients.

Figure 2. Areas under the curve (AUC) of receiver operating characteristic (ROC) curves using miR-181a-2-3p for (A) differentiating patients with MDS from normal controls, and (B) distinguishing sAML from newly diagnosed MDS patients.

Figure 3. Kaplan–Meier survival curves of newly diagnosed MDS patients (n = 54) with different levels of miR-181a-2-3p expression.

Figure 3. Kaplan–Meier survival curves of newly diagnosed MDS patients (n = 54) with different levels of miR-181a-2-3p expression.

Table 3. Uni/multivariate analysis of overall survival for MDS patients excluded sAML.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.